Background
Candidates for cardiac resynchronization therapy (CRT) receive either a biventricular pacemaker (CRT-P) or a biventricular pacemaker with an implantable-cardioverter defibrillator (ICD; CRT-D). Optimal device selection remains challenging as the benefit of ICD therapy may not be uniform, particularly in patients at competing risk of non-sudden death.
Methods and Results
In this serial cross-sectional study using the National Inpatient Sample database, we identified 311,086 admissions associated with CRT implant between 2006-2012. CRT-D was the most common device-type (86.1%), including in patients ≥75 years old with 5 or more Elixhauser comorbidities (75.5%). Multivariate predictors of CRT-D implant included demographic, clinical, and geographic factors: prior ventricular arrhythmia (rate ratio [RR], 1.14; 95% CI, 1.13-1.14), ischemic heart disease (RR, 1.11; 95% CI, 1.10-1.11), male gender (RR, 1.10; 95% CI, 1.09-1.10), black race (RR, 1.06; 95% CI: 1.04-1.07), and Northeast geographic region (RR, 1.06; 95% CI, 1.04-1.09). There was significant inter-hospital variation in the use of CRT-D (10-90 percentile range, 72.9% to 98.0% CRT-D).
Conclusions
The majority of patients in this contemporary US cohort underwent implantation of CRT-D. Predictors of CRT-D implant included demographic, clinical, and geographic factors. In patient subgroups predicted to have an attenuated benefit from ICD therapy (older adults with multiple comorbidities), CRT-D remained the dominant device type. An improved understanding of the determinants of device selection may aid in decision-making and ultimately better align patient risk with device benefit at the time of CRT implantation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.